Previous 10 | Next 10 |
YAVNE, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the first quarter ended March 31, 2024 on Wednesday, May 29, 2024. ...
Oral presentations include additional comparative data between EscharEx ® and SANTYL ® , and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the planned design and endpoints of the upcoming Phase II...
Shares of MediWound Ltd. (NASDAQ: MDWD) traded at a new 52-week high today and are currently trading at $17.39. So far today, approximately 35,312 shares have been exchanged, as compared to an average 30-day volume of 101.83k shares. MediWound Ltd., a biopharmaceutical company, develops, manu...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 50.1% to $0.1783 on volume of 599,794,977 shares WiSA Technologies Inc. (WISA) rose 248.6% to $6.1 on volume of 197,912,579 shares PROSHARES TRUST (SQQQ) rose 0.0% to $11.44 on volume of 182,001,060 shar...
2024-03-21 11:54:03 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips MediWound (NASDAQ: MDWD ) just reported results for the fourth quarter of 2023. MediWound reported earnings per share of -19 cents. This was above the analyst estimate for...
2024-03-21 11:35:23 ET MediWound Ltd. (MDWD) Q4 2023 Earnings Conference Call March 21, 2024, 08:30 AM ET Company Participants Gaia Shamis - LifeSci Advisors Ofer Gonen - Chief Executive Officer Barry Wolfenson - Executive Vice President of Strategy & Corpora...
2024-03-21 07:19:09 ET More on MediWound MediWound stock climbs 9% on Phase 2 data for wound care treatment FDA accepts MediWound application for NexoBrid pediatric approval Seeking Alpha’s Quant Rating on MediWound Historical earnings data for MediWou...
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...
$19 million revenue in 2023; $24 million projected revenue in 2024 NexoBrid ® commercially launched in U.S., Japan, India Potential blockbuster EscharEx ® to begin Phase III in the second half of 2024 $42 million cash runway through profitabilit...
2024-03-20 11:29:28 ET More on MediWound MediWound stock climbs 9% on Phase 2 data for wound care treatment FDA accepts MediWound application for NexoBrid pediatric approval Seeking Alpha’s Quant Rating on MediWound Historical earnings data for MediWou...
News, Short Squeeze, Breakout and More Instantly...
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in ne...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...